Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
nonsteroidal anti-inflammatory drug |
| gptkbp:approvalYear |
1999
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
M01AH02
|
| gptkbp:brand |
gptkb:Vioxx
|
| gptkbp:CASNumber |
162011-90-7
|
| gptkbp:chemicalFormula |
C17H14O4S
|
| gptkbp:discoveredBy |
gptkb:Merck_&_Co.
|
| gptkbp:eliminationHalfLife |
17 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
rofecoxib
|
| gptkbp:IUPACName |
4-(4-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone
|
| gptkbp:legalStatus |
withdrawn
|
| gptkbp:mechanismOfAction |
nonsteroidal anti-inflammatory drug
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:molecularWeight |
314.36 g/mol
|
| gptkbp:retired |
increased risk of cardiovascular events
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
heart attack
stroke edema hypertension gastrointestinal upset |
| gptkbp:usedFor |
osteoarthritis
pain relief rheumatoid arthritis dysmenorrhea |
| gptkbp:withdrawn |
2004
|
| gptkbp:bfsParent |
gptkb:nonsteroidal_anti-inflammatory_drug
gptkb:Vioxx |
| gptkbp:bfsLayer |
6
|